Cromos Pharma, where the patients are

R&D Trends

MD Anderson, GSK form immunotherapy collaboration

Thursday, April 10, 2014 02:00 PM

The University of TexasMD Anderson Cancer Center has formed a research alliance with global pharmaceutical developer GlaxoSmithKline (GSK) to strengthen its efforts in advancing therapies that train the body's immune system to combat cancer.

More... »

CRF Health eCOA webinar series

Eli Lilly, T1D Exchange collaborate on new initiatives to advance diabetes care

Thursday, April 10, 2014 01:56 PM

T1D Exchange, the first program of Unitio, a nonprofit organization that helps build patient community and research platforms dedicated to eradicating chronic diseases such as type 1 diabetes, and Eli Lilly have entered into a research collaboration that will enable both organizations to gain deeper, real-world insight about the experience of people with type 1 diabetes, to identify new ways to improve care and advance outcomes.

More... »


CEO Roundtable on Cancer launches data-sharing initiative to accelerate drug development

Thursday, April 10, 2014 01:03 PM

The CEO Roundtable on Cancer has launched Project Data Sphere, a new online oncology data-sharing platform using de-identified cancer patient information with the goal of accelerating drug discovery—by developing more efficient clinical trial protocols, epidemiological studies and, ultimately, new cancer therapies. 

More... »

Lieber Institute forms consortium to develop brain disorder treatments

Wednesday, April 9, 2014 12:31 PM

The Lieber Institute for Brain Development (LIBD), an independent nonprofit, and pharmaceutical companies Astellas, Eli Lilly, Lundbeck, Pfizer and Roche are participating in an early-stage research consortium to analyze RNA, the genomic and epigenetic data obtained from human brains. The goal of the consortium is to expand knowledge around the genetic contribution to brain disorders in the hope of identifying potential new treatment options.

More... »

Daiichi Sankyo, UCSF collaborate on neurodegenerative diseases

Wednesday, April 9, 2014 12:27 PM

Daiichi Sankyo and UC San Francisco (UCSF) have established a drug-discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases.

More... »

European researchers to submit proposals focused on curing virological diseases

Tuesday, April 8, 2014 02:41 PM

In a quest to cure chronic virological diseases such as HIV, hepatitis B and hepatitis C, Bristol-Myers Squibb has asked European researchers—notably junior faculty and young investigators—to submit innovative research ideas  to accelerate novel solutions as part of its Partnering for Cure program.

More... »

Merck, Ferring, WHO work to prevent post-partum hemorrhage

Monday, April 7, 2014 12:33 PM

Merck and Ferring Pharmaceuticals are collaborating with the World Health Organization (WHO) to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding (post-partum hemorrhage) in women after childbirth, which is designed to be stable at room temperature, even in hot and tropical climates (ICH climatic zone IV).

More... »

Rosetta Genomics, Marina Biotech ink alliance for rare diseases

Friday, April 4, 2014 12:02 PM

Rosetta Genomics, a developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, a nucleic acid-based drug discovery and development company focused on rare diseases, have established a strategic alliance to identify and develop microRNA-based products designed to diagnose and treat various neuromuscular diseases and dystrophies.

More... »

IntegraGen, Pfizer collaborate

Friday, April 4, 2014 12:00 PM

IntegraGen, a developer and marker of molecular diagnostic testing in oncology and autism, has entered into an agreement with Pfizer that provides Pfizer access to evaluate the company’s proprietary molecular signature for hepatocellular carcinoma. The 56-gene molecular signature covered by the agreement is intended to predict the clinical prognosis of patients with hepatocellular carcinoma and subcategorize patients into six separate classifications based on the molecular characteristics of their liver tumors.

More... »

Evotec, Debiopharm Group to collaborate on new treatment for cancer

Thursday, April 3, 2014 10:55 AM

Evotec has formed a research collaboration and licensing deal with Debiopharm Group, a Swiss-based global biopharmaceutical group, to identify and develop novel compounds having the potential to treat multiple forms of solid tumors and leukemia’s with defined genetic alterations. Discovery and preclinical development efforts will be driven by Evotec, while Debiopharm will manage clinical development. Evotec will receive R&D funding and high double-digit total payments triggered by clinical, regulatory and commercial milestones, plus royalties on sales of resulting commercial products.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs